posted Jun 12, 2018, 1:05 AM by Chong Ching Wern
[
updated Jun 12, 2018, 1:05 AM
]
12 June 2018 (Circular No. SP PPUM: 217/2018):
The following medications will be facing supply disruptions:
|
No.
|
Name of Medication
|
Formulary Category
|
Cause / Action by Pharmacy
|
Estimated Stock Recovery
|
Alternative Medication
|
1)
|
Fentanyl 100mcg/2mL Injection |
Standard Formulary |
· Raw material supply issues by Duopharma (M) Sdn. Bhd.
· Pharmacy Department has a balance stock of about 1500 ampoules only.
|
August 2018. |
Consider use of other medications which are available in our Standard Formulary. |
2)
|
Dexamethasone 8mg Injection (For IT use)
|
Standard Formulary |
· Production ceased.
· Raw materials were found not suitable for Intrathecal preparations.
|
N/A |
Consider use of IT Hydrocortisone Sodium Succinate 25mg/0.5mL Injection prepared by our Manufacturing Pharmacy. |
3)
|
Potassium Dihydrogen Phosphate 10mmol/10mL Injection |
Standard Formulary |
· Stock supply delivery delay by Pfizer (M) Sdn. Bhd.
|
Until further notice. |
None, Pfizer (M) Sdn. Bhd. is the sole manufacturer of the medication. |
4)
|
Lidocaine 1% Injection
|
Standard Formulary |
· Stock supply issues by Pfizer (M) Sdn. Bhd.
· Remaining stocks will solely be used for cases which require intravenous administration only.
|
N/A |
Ward stock supplies will be switched to Lidocaine 2% Injection. |
|
|
